ArticleFrontiers in public health2026
Practical dilemmas and communication reconstruction of patients' right to informed consent under the Civil Code.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From regulation to real legal cases: physician-patient disputes as a lens on universal health coverage governance in China, 2015-2025.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
China's Civil Code (2021) consolidates patients' right to informed consent and tightens the duty of disclosure owed by medical staff. In clinical practice, however, the substantive provisions of the Civil Code have not dissolved the persistent gap between statutory rule and everyday medical activity. This Policy and Practice Review diagnoses four interlocking practical dilemmas in the operation of the Code's informed-consent rule-covering defensive formalism, ambiguity over the decision-maker, the evidentiary architecture for consent and refusal, and the open-textured "inappropriate to explain" exception-and proposes a corresponding reconstruction along legal, cultural and technological dimensions, drawing on the reasonable-patient standard articulated in Canterbury v. Spence and Montgomery v. Lanarkshire Health Board (1, 2) and reaffirmed by the American Medical Association (3), the doctrine of therapeutic privilege as theorized by Faden and Beauchamp (4), and international guidance on informed-refusal documentation (5). By examining the institutional, cultural and technical factors contributing to these challenges, the article articulates implications for patient safety, equity for vulnerable populations, system-level trust and the dispute burden borne by clinicians and institutions, with a view to harmonizing legal compliance with humanistic, patient-centered care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.